logo
logo

Bioaffinity Technologies Receives Additional $7.7M From Exercise Of Warrants, Total Capital From Public Offering Increases To Approximately $15.6M

Sep 28, 2022•almost 3 years ago

Amount Raised

$7.7 Million

San AntonioTherapeuticsHealth CareBiotechnology

Description

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities.

Company Information

Company

bioAffinity Technologies

Location

San Antonio, Texas, United States

About

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Related People